Molecular Partners’ R&D Day in New York highlights progress of pipeline of DARPin® therapeutic candidates and dedicated research focus areas
The company announces plans to launch a second phase 2 clinical trial in multiple myeloma with MP0250, its proprietary lead asset in oncology Pamela Trail, the company's new CSO, highlights progress focusing the research team in several key areas, with the goal of producing a sustainable pipeline of DARPin® molecule IND candidates The company provides additional insight on its...
Read more









